Aprea Therapeutics, Inc. (NASDAQ:APRE) Sees Large Decrease in Short Interest

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the target of a large drop in short interest during the month of November. As of November 15th, there was short interest totalling 9,500 shares, a drop of 67.2% from the October 31st total of 29,000 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average daily volume of 22,000 shares, the short-interest ratio is currently 0.4 days.

Aprea Therapeutics Price Performance

Aprea Therapeutics stock opened at $2.98 on Thursday. Aprea Therapeutics has a 12-month low of $2.15 and a 12-month high of $8.85. The stock has a market capitalization of $16.18 million, a PE ratio of -1.06 and a beta of 0.97. The firm has a 50 day simple moving average of $3.31 and a 200-day simple moving average of $3.77.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.11. The company had revenue of $0.35 million for the quarter, compared to analysts’ expectations of $0.45 million. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%. On average, analysts forecast that Aprea Therapeutics will post -2.55 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have weighed in on APRE shares. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Aprea Therapeutics in a research note on Monday, November 18th. Wedbush restated an “outperform” rating and set a $11.00 price objective on shares of Aprea Therapeutics in a research note on Tuesday, August 13th.

Insider Buying and Selling

In other Aprea Therapeutics news, Director Marc Duey sold 6,462 shares of the company’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $4.58, for a total value of $29,595.96. Following the completion of the transaction, the director now owns 233,651 shares in the company, valued at approximately $1,070,121.58. This represents a 2.69 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Bernd R. Seizinger purchased 10,000 shares of the business’s stock in a transaction dated Friday, October 11th. The shares were acquired at an average cost of $2.68 per share, for a total transaction of $26,800.00. Following the acquisition, the director now owns 44,730 shares of the company’s stock, valued at approximately $119,876.40. The trade was a 28.79 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 42,290 shares of company stock valued at $165,096. Insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Dimensional Fund Advisors LP bought a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned approximately 0.20% of Aprea Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.